PTAB Institutes Review of Biogen’s Rituximab Patent


The PTAB has granted Celltrion’s petition for inter partes review of Biogen’s U.S. Patent 7,820,161.  (IPR2016-01614)  The patent is drawn to methods of treating rheumatoid arthritis by administration of rituximab.  Rituximab is sold by Biogen and Genentech under the trade-name Rituxan®.  Rituxan is FDA approved to treat non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.

This institution decision is posted along with other important IPR filings on biologic patents on our IPR tracker page.

Download PDF

Tagged with 

Comments are closed.